Perioperative handling of antiplatelet drugs. A critical appraisal

Current Drug Targets

Volumn 14, Issue 8, 2013, Pages 880-888

  Di Minno, Matteo Nicola Dario ^a   Milone, Marco ^a   Mastronardi, Pasquale ^a   Ambrosino, Pasquale ^a   Di Minno, Alessandro ^a   Parolari, Alessandro ^b   Tremoli, Elena ^b,c   Prisco, Domenico ^d  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CENTRO CARDIOLOGICO MONZINO   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

Author keywords

New antiplatelet drugs; Perioperative management; Thrombotic risk

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CANGRELOR; CLOPIDOGREL; PLACEBO; PRASUGREL; SARPOGRELATE; TICAGRELOR;

ACUTE CORONARY SYNDROME; BARE METAL STENT; BLEEDING; BLOOD TRANSFUSION; CARDIOVASCULAR RISK; CORONARY ARTERY THROMBOSIS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELUTING STENT; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; HEART INFARCTION; HUMAN; INCIDENCE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PEROPERATIVE COMPLICATION; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

BLOOD LOSS, SURGICAL; CARDIAC SURGICAL PROCEDURES; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; HUMANS; PERIOPERATIVE CARE; PERIOPERATIVE PERIOD; PLATELET AGGREGATION INHIBITORS; STENTS;

EID: 84881328773     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450111314080008     Document Type: Review

References (51)

1. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative Management of Antithrombotic Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl): e326S-50S.
2. Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet Drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl): e89S-e119S.
3. Di Minno MN, Russolillo A, Camera M, et al. New anti-thrombotic drugs for stroke prevention. Curr Vasc Pharmacol 2011; 9: 723-32.
4. Di Minno MN, Guida A, Camera M, Colli S, Di Minno G, Tremoli E. Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention. Ann Med 2011; 43: 531-44.
5. Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. A randomized trial (CREDO). JAMA 2002; 288: 2411-20.
6. Chassot PG, Delabays A, Spahn D. Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction. Br J Anaesth 99: 316-28.
7. Vicenzi MN, Meislitzer T, Heitzinger B, et al. Coronary artery stenting and non-cardiac surgery-a prospective outcome study. Br J Anaesth 2006; 96: 686-93
8. Kaluza GL, Joseph J, Lee JR, et al. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll Cardiol 2000; 35: 1288-94.
9. Collet JP, Montalescot G, Blanchet B et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndrome. Circulation 2004; 110: 2361-7.
10. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drugeluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364: 1519-21.
11. Sharma AK, Ajani AE, Hamwi SM, et al. Major noncardiac surgery following coronary stenting: when is it safe to operate? Catheter Cardiovasc Interv. 2004; 63: 141-5.
12. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drugeluting stents. JAMA 2005; 293: 2126-30.
13. Murphy JT, Brenda GF. Thrombosis of sirolimus-eluting coronary stent in the postanesthesia care unit. Anesth Analg 2005; 101: 971-3.
14. Newsome LT, Weller RS, Gerancher JC, Kutcher MA, Royster RL. Coronary artery stents. II. Perioperative considerations and management. Anesth Analg 2008; 107: 570-90.
15. Di Minno MN, Prisco D, Ruocco AL, Mastronardi P, Massa S, Di Minno G. Perioperative handling of patients on antiplatelet therapy with need for surgery. Intern Emerg Med 2009; 4: 279-88.
16. Korte W, Cattaneo M, Chassot PG, et al. Peri-operative management of antiplatelet therapy in patients with coronary artery disease: joint position paper by members of the working group on Perioperative Haemostasis of the Society on Thrombosis and Haemostasis Research (GTH), the working group on Perioperative Coagulation of the Austrian Society for Anesthesiology, Resuscitation and Intensive Care (ÖGARI) and the Working Group Thrombosis of the European Society for Cardiology (ESC). Thromb Haemost 2011; 105: 743-9.
17. Albaladejo P, Marret E, Samama CM, et al. Non-cardiac surgery in patients with coronary stents: the RECO study. Heart 2011; 97: 1566-72.
18. Mantz J, Samama CM, Tubach F, et al. Impact of preoperative maintenance or interruption of aspirin on thrombotic and bleeding events after elective non-cardiac surgery: the multicentre, randomized, blinded, placebo-controlled, STRATAGEM trial. Br J Anaesth 2011; 107: 899-910.
19. CAPRIE Sterring Committee. A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996; 348: 1329-39.
20. Stone DH, Goodney PP, Schanzer A, et al. Clopidogrel is not associated with major bleeding complications during peripheral arterial surgery. J Vasc Surg 2011; 54: 779-84.
21. Cerfolio RJ, Minnich DJ, Bryant AS. General thoracic surgery is safe in patients taking Clopidogrel (Plavix). J Thorac Cardiovasc Surg 2010; 140: 970-6.
22. Paul S, Stock C, Chiu YL, et al. Management and Outcomes of Patients on Preoperative Plavix (Clopidogrel)Undergoing General Thoracic Surgery. Thorac Cardiovasc Surg. 2012.[Epub ahead of print].
23. Collinge CA, Kelly KC, Little B, Weaver T, Schuster RD. The effects of Clopidogrel (Plavix) and other oral anticoagulants on early hip fracture surgery. J Orthop Trauma 2012; 26: 568-73.
24. Antolovic D, Rakow A, Contin P, et al. A randomised controlled pilot trial to evaluate and optimize the use of anti-platelet agents in the perioperative management in patients undergoing general and abdominal surgery-the APAP trial (ISRCTN45810007). Langenbecks Arch Surg 2012; 397: 297-306.
25. Illuminati G, Ceccanei G, Pacilè MA, Pizzardi G, Palumbo P, Vietri F. Dual antiplatelet treatment in patients candidates for abdominal surgery. Ann Ital Chir 2012[Epub ahead of print].
26. O'Riordan JM, Margey RJ, Blake G, O'Connell PR. Antiplatelet agents in the perioperative period. Arch Surg 2009; 144: 69-76.
27. Berger JS, Frye CB, Harshaw Q, et al. Impact of Clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis. J Am Coll Cardiol 2008; 52: 1693-701.
28. Mehta RH, Roe MT, Mulgund J, et al. Acute Clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery. J Am Coll Cardiol 2006; 48: 281-6.
29. Cruden NL, Morch K, Wong DR, Klinke WP, Ofiesh J, Hilton JD. Clopidogrel loading dose and bleeding outcomes in patients undergoing urgent coronary artery bypass grafting. Am Heart J 2011; 161: 404-10.
30. Fox KA, Mehta SR, Peters R, et al. Benefits and risks of the combination of Clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) trial. Circulation 2004; 110: 1202-8.
31. Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris VA, Brown JR, et al. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 2011; 91: 944-82.
32. Hansson EC, Dellborg M, Lepore V, Jeppsson A. Prevalence, indications and appropriateness of antiplatelet therapy in patients operated for acute aortic dissection: associations with bleeding complications and mortality. Heart 2013; 99: 116-21.
33. Savonitto S, D'Urbano M, Caracciolo M, et al. Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of 'bridging' antiplatelet therapy with tirofiban during temporary withdrawal of Clopidogrel. Br J Anaesth 2010; 104: 285-91.
34. Savonitto S, Caracciolo M, Cattaneo M, De Servi S. Management of patients with recently implanted coronary stents on dual antiplatelet therapy who need to undergo major surgery. J Thromb Haemost 2011; 9: 2133-42.
35. Rassi AN, Blackstone E, Militello MA, et al. Safety of Bridging With Eptifibatide for Patients With Coronary Stents Before Cardiac and Non-Cardiac Surgery. Am J Cardiol 2012; 110: 485-90.
36. Di Minno MN, Momi S, Di Minno A, Russolillo A. Stroke prevention: from available antiplatelet drugs to novel molecular targets. Curr Drug Targets 2013; 14: 3-12.
37. Angiolillo DJ, Bhatt DL, Gurbel PA, Jennings LK. Advances in antiplatelet therapy: agents in clinical development. Am J Cardiol 2009; 103: 40A-51A
38. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus Clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-15.
39. Anderson SD, Shah NK, Yim J, Epstein BJ. Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist. Ann Pharmacother 2010; 44: 524-37.
40. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus Clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-57.
41. Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009; 361: 2318-29.
42. Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009; 361: 2330-41.
43. Angiolillo DJ, Firstenberg MS, Price MJ, et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 2012; 307: 265-74.
44. Shinohara Y, Nishimaru K, Sawada T, for S-ACCESS Study Group. Sarpogrelate-SarpoAspirin comparative clinical study for efficacy and safety in secondary prevention of cerebral infarction (S-ACCESS): a randomized, double-blind, aspirin controlled trial. Stroke 2008; 39: 1827-33.
45. Akin I, Schneider H, Ince H, et al. Second-and third-generation drug-eluting coronary stents: progress and safety. Herz 2011; 36: 190-6.
46. Kandzari DE, Leon MB. Overview of pharmacology and clinical trials program with the zotarolimus-eluting endeavor stent. J Interv Cardiol 2006; 19: 405-13.
47. Massa M, Rosti V, Ferrario M, et al. Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood 2005; 105: 199-206.
48. Flugelman MY, Dichek DA. Seeding of intracoronary stents with endothelial cells: current status and future prospects. J Interv Cardiol 1995; 8: 383-5.
49. Finn AV, Nakazawa G, Joner M, et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 2007; 27: 1500-10.
50. Piscione F, Cassese S, Galasso G, et al. A new approach to percutaneous coronary revascularization in patients requiring undeferrable non-cardiac surgery. Int J Cardiol 2011; 146: 399-403.
51. Cassese S, Galasso G, Sciahbasi A, et al. Antiplatelet theRapy after Genous EPC-capturing coroNary stenT implantatiOn: The ARGENTO Study: a prospective, multicenter registry. Int J Cardiol 2012[Epub ahead of print].